1. Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement study, all patients in the canagliflozin arm started with the 100-mg dose; 85% of patients increased their dose to 300 mg during the study.
Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement study, all patients in the canagliflozin arm started with the 100-mg dose; 85% of patients increased their dose to 300 mg during the study. BP, blood pressure; CANA, canagliflozin; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; LS, least squares; MET, metformin; PBO, placebo; SE, standard error; SITA, sitagliptin.
Richard E. Pratley, and Eugenio Cersosimo Clin Diabetes 2017;35:
©2017 by American Diabetes Association